UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q/A
Amendment No. 1
| |
|
|
| þ |
|
Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 |
For
the Quarterly Period ended March 31, 2009
| |
|
|
| o |
|
Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 |
For the Transition Period from to
Commission File Number 001-33043
ImaRx Therapeutics, Inc.
(Exact Name of Registrant as Specified in Its Charter)
| |
|
|
| Delaware
|
|
86-0974730 |
| (State or Other Jurisdiction of
|
|
(I.R.S. Employer |
| Incorporation or Organization)
|
|
Identification No.) |
| |
|
|
| ImaRx Therapeutics, Inc. |
|
|
| c/o Stoel Rives LLP |
|
|
| 201 S. Main Street, Suite 1100 |
|
|
| Salt Lake City, Utah
|
|
84111 |
| (Address of Principal Executive Offices)
|
|
(Zip Code) |
(801) 578-6962
(Registrant’s Telephone Number, Including Area Code)
Indicate by check mark whether the registrant (1) has filed all reports required to be filed
by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or
for such shorter period that the registrant was required to file such reports), and (2) has been
subject to such filing requirements for at least the past 90 days. YES þ NO o
Indicate by check mark whether the registrant has submitted electronically and posted on its
corporate Web site, if any, every Interactive Data File required to be submitted and posted
pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months
(or for such shorter period that the registrant was required to submit and post such files). YES
o NO o
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated
filer, a non-accelerated filer or a smaller reporting company. See the definitions of “large
accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the
Exchange Act. (Check one):
| |
|
|
|
|
|
|
| Large accelerated filer o
|
|
Accelerated filer o
|
|
Non-accelerated filer o
|
|
Smaller reporting company þ |
|
|
|
|
|
(Do not check if a smaller reporting company) |
|
|
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of
the Exchange Act). YES
o NO
þ
The number of shares outstanding of each of the issuer’s classes of common stock, as of the
latest practicable date is as follows:
| |
|
|
| Class
|
|
Outstanding at December 29, 2009 |
|
|
|
|
| Common Stock $0.0001 par value
|
|
11,665,733 |
EXPLANATORY NOTE
ImaRx Therapeutics, Inc. (the “Company”) is filing this Amendment No. 1 to its Quarterly
Report on Form 10-Q for the quarter ended March 31, 2009 (the “Report”) for the sole purpose of
amending Exhibit Nos. 31.1 and 31.2 to include the introductory language of paragraph 4 and the
language of paragraph 4(b) of Item 601(b)(31) Regulation S-K
Except as described above, no other changes are made to Report, and this Form 10-Q/A does
not amend, update or change any other Item or the disclosures in the Report in any way. This Form
10-Q/A does not reflect events occurring after the filing of the Report or modify or update those
disclosures, including any exhibits to the Report, affected by subsequent events.
Item 6. Exhibits.
Exhibits
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
Incorporated by Reference |
| Exhibit |
|
|
|
Filed |
|
|
|
Exhibit |
|
|
|
|
| No. |
|
Exhibit Title |
|
Herewith |
|
Form |
|
No. |
|
File No. |
|
Filing Date |
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
31.1 |
|
|
Rule 13a-14(a)/15d-14(a) Certification
of Principal Executive Officer
|
|
X |
|
|
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
31.2 |
|
|
Rule 13a-14(a)/15d-14(a) Certification
of Principal Financial Officer
|
|
X |
|
|
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
32 |
|
|
Section 1350 Certification of Periodic
Financial Report by the Chief Executive
Officer and Principal Financial and
Accounting Office
|
|
|
|
10-Q
|
|
|
32 |
|
|
001-33043
|
|
May 14, 2009 |
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly
caused this report on Form 10Q/A to be signed on its behalf by the undersigned, thereunto duly authorized.
| |
|
|
|
|
| |
IMARX THERAPEUTICS, INC.
|
|
| Date: December 29, 2009 |
By: |
/s/ RICHARD LOVE
|
|
| |
|
Richard Love, |
|
| |
|
Chairman of the Board
(Principal Executive Officer and Principal Financial Officer) |
|
3